Literature DB >> 19426405

Evaluation of potential visual acuity in eyes with macular oedema secondary to retinal vein occlusion.

Atsushi Sakamoto1, Akitaka Tsujikawa, Masafumi Ota, Noritatsu Yamaike, Yuriko Kotera, Kazuaki Miyamoto, Mihori Kita, Nagahisa Yoshimura.   

Abstract

PURPOSE: To evaluate the potential visual acuity (VA) of eyes with macular oedema (MO) associated with retinal vein occlusion (RVO).
METHODS: Thirty-one eyes of 31 patients with MO associated with RVO were examined and then treated with an intravitreal injection of bevacizumab. Of these 31 eyes, 22 showed complete resolution of the MO at 1 month after treatment, at which time potential VA was determined; 12 eyes had good function and 10 had poor function at this time. Optical coherence tomography was used to detect the junctions between inner and outer segments of the photoreceptors (IS/OS) as a hallmark of integrity of the outer photoreceptor layer.
RESULTS: In the poor function group, pretreatment VA was significantly worse (P = 0.0106) and pretreatment central macular thickness was significantly greater (P = 0.0121). Preservation of the foveal photoreceptor layer before treatment was associated closely with good visual function after resolution of MO, and IS/OS line beneath the fovea was detected more frequently before treatment in eyes with good function (P = 0.0053).
CONCLUSIONS: In eyes with MO associated with RVO, when the IS/OS line was detected beneath the fovea, they would be expected to have good vision after resolution of the MO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426405     DOI: 10.1111/j.1442-9071.2009.01914.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion.

Authors:  Masafumi Ota; Akitaka Tsujikawa; Kazuaki Miyamoto; Atsushi Sakamoto; Tomoaki Murakami; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-12-30       Impact factor: 2.447

3.  Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab.

Authors:  Tatsuya Yunoki; Akio Miyakoshi; Tomoko Nakamura; Kazuya Fujita; Chiharu Fuchizawa; Atsushi Hayashi
Journal:  Jpn J Ophthalmol       Date:  2012-01-14       Impact factor: 2.447

Review 4.  Mechanisms of vision loss in eyes with macular edema associated with retinal vein occlusion.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2018-03-23       Impact factor: 2.447

5.  Association between photoreceptor integrity and visual outcome in diabetic macular edema.

Authors:  Hyun Jin Shin; Seung Hyen Lee; Hyewon Chung; Hyung Chan Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-27       Impact factor: 3.117

6.  Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion.

Authors:  Akiko Fujihara-Mino; Yoshinori Mitamura; Naoki Inomoto; Hiroki Sano; Kei Akaiwa; Kentaro Semba
Journal:  Clin Ophthalmol       Date:  2016-07-18

7.  A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion.

Authors:  Peirong Huang; Wenquan Niu; Zhentian Ni; Renzuo Wang; Xiaodong Sun
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

8.  Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure.

Authors:  Haiyang Liu; Suyan Li; Zhengpei Zhang; Jie Shen
Journal:  Exp Ther Med       Date:  2017-11-03       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.